

# J William L Brown

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6098367/publications.pdf>

Version: 2024-02-01

18  
papers

1,284  
citations

759055

12  
h-index

839398

18  
g-index

19  
all docs

19  
docs citations

19  
times ranked

1945  
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 175.	3.8	336
2	Association of Obstructive Sleep Apnea With Risk of Serious Cardiovascular Events. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 720-728.	0.9	294
3	Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. <i>Lancet Neurology</i> , The, 2020, 19, 307-316.	4.9	219
4	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. <i>Lancet Neurology</i> , The, 2017, 16, 271-281.	4.9	134
5	An abnormal periventricular magnetization transfer ratio gradient occurs early in multiple sclerosis. <i>Brain</i> , 2017, 140, 387-398.	3.7	62
6	Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study. <i>Lancet Neurology</i> , The, 2021, 20, 709-720.	4.9	44
7	Surface-in pathology in multiple sclerosis: a new view on pathogenesis?. <i>Brain</i> , 2021, 144, 1646-1654.	3.7	31
8	Long-term remission with rituximab in refractory leucine-rich glioma inactivated 1 antibody encephalitis. <i>Journal of Neuroimmunology</i> , 2014, 271, 66-68.	1.1	30
9	Alemtuzumab: evidence for its potential in relapsing&ndash;remitting multiple sclerosis. <i>Drug Design, Development and Therapy</i> , 2013, 7, 131.	2.0	26
10	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. <i>Brain</i> , 2020, 143, 2742-2756.	3.7	24
11	Amphetamine&acirc;associated seizures: Clinical features and prognosis. <i>Epilepsia</i> , 2011, 52, 401-404.	2.6	23
12	Keratinocyte growth factor impairs human thymic recovery from lymphopenia. <i>JCI Insight</i> , 2019, 4, .	2.3	16
13	Magnetisation transfer ratio abnormalities in primary and secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 679-687.	1.4	11
14	Remyelination in humans due to a retinoid&acirc;X receptor agonist is age&acirc;dependent. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 1090-1094.	1.7	10
15	The role of MRI in the evaluation of secondary progressive multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 157-171.	1.4	8
16	Clinician and patient experience of neurology telephone consultations during the COVID-19 pandemic. <i>Postgraduate Medical Journal</i> , 2022, 98, 533-538.	0.9	7
17	Periventricular magnetisation transfer ratio abnormalities in multiple sclerosis improve after alemtuzumab. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1093-1101.	1.4	6
18	Determinants of therapeutic lag in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1838-1851.	1.4	3